Measurement of ab-initio physiomarker using wearable sensors to predict aneurysm growth and formation

使用可穿戴传感器测量从头开始的生理标志物以预测动脉瘤的生长和形成

• 批准号: 10802098
• 负责人: Tom Yu Zhao
• 金额: $ 6.91万
• 依托单位: NORTHWESTERN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10802098
• 关键词: 4D MRI; Abdominal Aortic Aneurysm; Affect; Aneurysm; Angiography; Aorta; Aortic Aneurysm; Area Under Curve; Automobile Driving; Biomechanics; Biosensor; Blood Pressure Monitors; Blood Vessel Prosthesis; Blood Vessels; Blood Viscosity; Blood flow; Clinical; Coupling; Data; Data Collection; Development; Diagnosis; Diameter; Dissection; Echocardiography; Encapsulated; Evaluation; Evolution; Exclusion Criteria; Exhibits; Experimental Models; General Population; Growth; Health; Healthcare; Home; Human body; Hypertension; Image; In Vitro; Intervention; Judgment; Liquid substance; Location; Magnetic Resonance Imaging; Marfan Syndrome; Measurement; Measures; Methods; Modality; Monitor; Observational Study; Operative Surgical Procedures; Pathologic; Patients; Periodicity; Physiological; Population Statistics; Prevalence; Process; Property; ROC Curve; Recommendation; Recording of previous events; Research Project Grants; Retrospective Studies; Retrospective cohort study; Risk; Risk Reduction; Rupture; Ruptured Aneurysm; Site; Skin; Structure; System; Thoracic aorta; Time; Tissues; Training; Work; X-Ray Computed Tomography; aortic valve; bicuspid aortic valve; checkup examination; clinical decision-making; cohort; comorbidity; diagnostic strategy; experimental study; flexibility; follow-up; hemodynamics; in-vivo diagnostics; inclusion criteria; individual patient; kinematics; mortality; pressure; profiles in patients; prospective; risk prediction; screening; sensor; shear stress; standard of care; surgery outcome; surveillance strategy; theories; wearable sensor technology

Project Summary Aneurysms are permanent, local dilations of the blood vessel. The growth, rupture and dissection of aortic aneurysms induce a significant rate of patient mortality. The current standard of care relies on a reactive strategy of surveillance over a period of 1 to 5 years to monitor the growth rate of an aneurysm. This project seeks to validate the predictive accuracy of an ab-initio physiomarker in diagnosing both the growth and dissection of an aneurysm during an initial evaluation. By capturing the underlying physical mechanism driving aneurysm development, the physiomarker can be used to determine whether a cross section of the blood vessel will dilate permanently—whether an aneurysm will grow or remain stagnant over time. This predictive strategy can inform immediate treatment or surgical intervention at the initial evaluation of the patient instead of waiting until follow-up to monitor for growth. The specific aims of the project are threefold. The first is to verify the biomechanical accuracy of the physiomarker, determine its relationship with tissue remodeling modalities, and quantify nonlinear effects using an established in vitro experiment. The hemodynamic and vessel wall properties will be controlled to examine the growth and stagnation regimes. The second is to validate the accuracy of the physiomarker in patients with associated aortopathies like Marfan syndrome or biscuspid aortic valves, which may typically act as confounding factors for regression-based methods but are not expected to affect this ab-initio framework. Retrospective observational studies will be performed to examine the accuracy of the physiomarker in the presence of these factors. Lastly, the physiomarker will be measured using flexible, wearable sensors, either in conjunction with echocardiography or as a standalone platform. This will be carried out via carefully controlled, prospective observational studies over 1 to 2 years. Both modalities will offer a safer, cheaper and more accurate way to predict aneurysm growth and dissection. If the standalone sensor platform exhibits sufficient accuracy in measuring the physiomarker, it will enable more frequent, at home monitoring of aneurysms, akin to how blood pressure monitors can be used to track the development of hypertension. Additionally, it will enable much broader screening for aneurysms in the general population as part of routine health checkups.

项目概要 动脉瘤是血管的永久性局部扩张。生长、破裂和 主动脉瘤夹层导致患者死亡率显着升高。目前的 标准护理依赖于 1 至 5 年期间的反应性监测策略 监测动脉瘤的生长速度。该项目旨在验证预测的准确性 诊断动脉瘤生长和夹层的从头算生理标志物 初步评估。通过捕捉驱动动脉瘤的潜在物理机制 发育过程中，生理标志物可用于确定血液的横截面是否 血管将永久扩张——无论动脉瘤会随着时间的推移而生长还是保持停滞。 这种预测策略可以在最初的时候为立即治疗或手术干预提供信息 对患者进行评估，而不是等到随访才监测生长情况。具体的 该项目有三个目标。首先是验证生物力学的准确性 生理标志物，确定其与组织重塑方式的关系，并量化 使用已建立的体外实验的非线性效应。血流动力学和血管壁 将控制属性以检查增长和停滞状态。第二个是 验证患有马凡氏症等相关主动脉病的患者的生理标志物的准确性 综合征或二叶式主动脉瓣，通常可能作为混杂因素 基于回归的方法，但预计不会影响这个从头开始的框架。回顾性 将进行观察性研究以检查生理标志物的准确性 这些因素的存在。最后，将使用灵活的可穿戴设备来测量生理标记 传感器，可以与超声心动图结合使用，也可以作为独立平台。这将是 通过 1 至 2 年的仔细控制、前瞻性观察研究进行。两个都 模式将提供更安全、更便宜和更准确的方法来预测动脉瘤的生长和 解剖。如果独立传感器平台在测量时表现出足够的精度 生理标记物，它将能够更频繁地在家监测动脉瘤，类似于如何 血压计可用于追踪高血压的发展情况。此外，它 作为常规的一部分，将能够对普通人群进行更广泛的动脉瘤筛查 健康检查。